Sydney, Sep 23, 2014 - (ABN Newswire) - Regenerative medicine company, Regeneus Ltd (ASX:RGS), today announced plans to open the HiQCell Regenerative Medicine Clinic in Singapore, and the appointment of leading specialist sports physician, Dr Patrick Goh, as Medical Director.
Through the clinic, Dr Goh will provide patients in Singapore with access to Regeneus’ HiQCell, an innovative cell therapy for the treatment of osteoarthritis, with first treatments expected to commence in late 2014. As well as assuming the role of Medical Director, at the HiQCell Regenerative Medicine Clinic, Dr Goh will become the initial treating medical practitioner for the HiQCell procedure.
Dr Goh is a leading sports medicine specialist who was chief medical officer for Team Singapore during the 2000 and 2004 Olympic Games. He holds a n umber of positions within Singapore’s Ministry of Health, the Singapore Armed Forces and Defence Science Organisation (DSO) and the National Anti-Doping Advisory Board.
Dr Goh said, “HiQCell provides a viable treatment option for mid-stage, age or impact related osteoarthritis patients who might otherwise face ongoing debilitating pain, loss of function, inability to play sport and reduced quality of life. I am very pleased to be able to offer this treatment to my patients.”
The HiQCell Regenerative Medicine Clinic will be located at the prestigious Camden Medical Centre in Singapore’s premier medical services district on Orchard Road where a new state of the art cell-processing laboratory has been established.
Singapore provides a natural first overseas market for HiQCell as it is recognised as a leading edge medical services hub for both local and international patient treatments.
Regeneus Commercial Development Director for Huma n Health, Steven Barbera, said, “We are delighted to be partnering with Dr Goh at what will be a first class medical facility within Camden Medical Centre, to deliver high quality outcomes for patients.”
Regeneus CEO, Professor Graham Vesey said, “This is a very exciting announcement for Regeneus as it reports against a major milestone and highlights the first location for treatment of HiQCell outside of Australia. It makes good sense for Regeneus from a business perspective to select Singapore as the first international location for the delivery of our HiQCell treatment, as the regulatory environment is similar to what we’re used to in Australia and the standard of care is very high.”
The HiQCell treatment involves harvesting a small amount of a patient’s own stem cells from their adipose (fat) tissue and after separating and concentrating the regenerative cells these are re-injected in osteoarthritic-affected joints such as knees, hips and ankles. The HiQCell treatment, which aims to reduce inflammation and repair damaged tissue is carried out under the supervision of the treating medical practitioner. HiQCell has been used to treat more than 500 patients and over 1,000 arthritic joints. The cell therapy procedure is supported by safety data from a randomised controlled clinical trial and long-term safety and efficacy data is tracked through Australia’s first Joint Registry for stem cell therapy.
About Dr Patrick Goh:
Dr Goh is a registered specialist in Sports Medicine, practicing at Sports Medicine International, part of the Orthopaedics International group in Singapore. He received his medical degree from the National University of Singapore in 1984 before going on to further studies in sports medicine in the USA.
A clinician for 30 years, he worked previously with the rehabilitation medicine department of Singapore General Hospital, and the Singapore Sports Council’s (SSC) Sports Medi cine and Research Centre, where his patients ranged from recreational athletes to the country’s top sportsmen and women. He was Chief Medical Officer for Team Singapore for the 2000 and 2004 Olympic Games, and team physician to numerous regional games.
Dr Goh pioneered the use of musculoskeletal ultrasound as an in-clinic tool for evaluation and imagingguided treatment of sports and musculoskeletal injuries, in particular, ultrasound-guided Extracorporeal Shock-Wave Therapy (ESWT). In 2008, leveraging on his familiarity with musculoskeletal ultrasound, he became the first sports physician in Singapore to use Platelet-Rich Plasma (PRP) for the targeted treatment of sports injuries. His work in this area led to numerous invitations to speak on this topic at home and internationally, as he continues to have an ongoing interest in biological solutions for musculoskeletal and sports injuries.
In addition to his private sports medicine practice, Dr Goh is curr ently Co-Chair of the Sports Medicine Subspecialty Training Committee under the Ministry of Health, and is an examiner for the Sports Medicine Advanced Specialty Training exams. He is Deputy Chairman for the institutional review board of the Singapore Armed Forces and the Defence Science Organisation (DSO). Dr. Goh also holds appointments as Chairman of the National Anti-Doping Advisory Board for Singapore and Chairman of the South-East Asian Regional Anti-Doping Organisation (SEARADO). He is an elected board member of the Institute of National Anti-Doping Organisation (iNADO). http://www.ortho-intl.com/index.php/dr-patrick-goh
About Camden Medical Centre:
Camden Medical Centre’s exclusive, multi-disciplinary community includes leading medical specialists and healthcare professionals in plastic surgery, ophthalmology, obstetrics and gynaecology, dentistry, family medicine, pediatrics, aesthetic medicine, neurology, psychiatry, rehabilitation therapy and sports medicine.
At Camden, every medical clinic and healthcare centre is committed to providing the quality care and premium service. This provides peace of mind to all local and international patients who are seeking worldclass healthcare.
http://www.camdenmedical.com
WEB: HiQCell Regenerative Medicine Clinic to o pen in Singapore
About: Regeneus Ltd
Regeneus Ltd (ASX:RGS) is a Sydney-based ASX listed regenerative medicine company that develops and commercialises stem cell and other biological therapies for the human and veterinary health markets with a focus on musculoskeletal and oncology conditions. The company has a marketed autologous (patient’s cells) product using adipose (fat) derived stem cells to treat human osteoarthritis (OA), HiQCell, which has been used to treat over 1000 arthritic joints. The company plans to commence a clinical trial of allogeneic (donor cells) adipose stem cells to treat human OA in Q2 2015.
Contact:
Investors:
Sandra McIntosh
Company Secretary
Regeneus Ltd
T: +61 2 9499 8010
E: investors@regeneus.com.au
W: www.regeneus.com.au
Practitioner and Patient Enquiries:
Steven Barbera
Commercial Development Director
Human Health Regeneus Ltd
T: +61 2 9499 8010
E: patientenquiries@regeneus.com.au
Mr Bou Leong Lai
Director
Regeneus South East Asia Pte Ltd
T: +65 9617 8501
E: patientenquiries@regeneus.com.au
Help employers find you! Check out all the jobs and post your resume.
